Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Publisher Correction: Crohn's disease.
Roda G, Ng SC, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Roda G, et al. Among authors: panaccione r. Nat Rev Dis Primers. 2020 Apr 6;6(1):26. doi: 10.1038/s41572-020-0172-2. Nat Rev Dis Primers. 2020. PMID: 32251284
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ. Peyrin-Biroulet L, et al. Among authors: panaccione r. Am J Gastroenterol. 2012 Dec;107(12):1770-6. doi: 10.1038/ajg.2012.117. Am J Gastroenterol. 2012. PMID: 23211844
Evolving definitions of remission in Crohn's disease.
Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ. Panaccione R, et al. Inflamm Bowel Dis. 2013 Jul;19(8):1645-53. doi: 10.1097/MIB.0b013e318283a4b3. Inflamm Bowel Dis. 2013. PMID: 23598817
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Peyrin-Biroulet L, et al. Among authors: panaccione r. Am J Gastroenterol. 2015 Sep;110(9):1324-38. doi: 10.1038/ajg.2015.233. Epub 2015 Aug 25. Am J Gastroenterol. 2015. PMID: 26303131 Review.
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. Colombel JF, et al. Among authors: panaccione r. Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18. Gut. 2017. PMID: 26893500 Free PMC article.
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group. Regueiro M, et al. Gastroenterology. 2016 Jun;150(7):1568-1578. doi: 10.1053/j.gastro.2016.02.072. Epub 2016 Mar 3. Gastroenterology. 2016. PMID: 26946343 Free article. Clinical Trial.
Long-term Efficacy of Vedolizumab for Crohn's Disease.
Vermeire S, Loftus EV Jr, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. Vermeire S, et al. Among authors: panaccione r. J Crohns Colitis. 2017 Apr 1;11(4):412-424. doi: 10.1093/ecco-jcc/jjw176. J Crohns Colitis. 2017. PMID: 27683798 Clinical Trial.
416 results